Quek Marcus L, Penson David F
Department of Urology, Keck School of Medicine at the University of Southern California, Los Angeles, CA 90089, USA.
Urol Oncol. 2005 May-Jun;23(3):208-15. doi: 10.1016/j.urolonc.2005.03.003.
To date, there are no studies conclusively documenting that one treatment for localized prostate cancer is superior to another in terms of overall survival. Therefore, patients must consider other outcomes when choosing primary therapy for localized disease. One of the most important factors patients consider when choosing their treatment is the effect of therapy on their quality of life (QOL). Over the past decade, there have been an increasing number of studies assessing health related QOL (HRQOL) outcomes in localized prostate cancer. The goal of this article is to review our current understanding of HRQOL in this disease. We will begin by examining the established HRQOL instruments for use in localized prostate cancer. We will then discuss the effect of various treatments on QOL and review the literature comparing HRQOL outcomes between therapies.
迄今为止，尚无研究能确凿证明针对局限性前列腺癌的一种治疗方法在总生存期方面优于另一种治疗方法。因此，患者在选择局限性疾病的初始治疗时必须考虑其他结局。患者在选择治疗方法时考虑的最重要因素之一是治疗对其生活质量（QOL）的影响。在过去十年中，评估局限性前列腺癌患者健康相关生活质量（HRQOL）结局的研究越来越多。本文的目的是回顾我们目前对该疾病中HRQOL的理解。我们将首先研究用于局限性前列腺癌的既定HRQOL工具。然后，我们将讨论各种治疗对生活质量的影响，并回顾比较不同治疗方法之间HRQOL结局的文献。
Zotero 插件